<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7104000/results/search/test_trace/results.xml">
  <result pre="coronavirus disease 2019 (COVID-19) spreads, efforts are being made to" exact="reduce transmission" post="via standard public health interventions based on isolation of"/>
  <result pre="to reduce transmission via standard public health interventions based on" exact="isolation" post="of cases and tracing of contacts. In their modelling"/>
  <result pre="standard public health interventions based on isolation of cases and" exact="tracing" post="of contacts. In their modelling study, Joel Hellewell and"/>
  <result pre="by Hellewell and colleagues is that all individuals with symptomatic" exact="infection" post="with severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2)"/>
  <result pre="outbreak began. A second assumption of the model is that" exact="isolation" post="of cases is 100% effective in stopping transmission. Yet"/>
  <result pre="been recommended by WHO for people at high risk of" exact="infection" post="before or after exposure to pandemic influenza.3 Antiviral drugs"/>
  <result pre="onset and lasts up to 14 days), and targeted prophylactic" exact="treatment" post="of contacts could reduce their risk of becoming infected.3"/>
  <result pre="reduce their risk of becoming infected.3 The implementation of antiviral" exact="treatment" post="and prophylaxis has several requirements. The stockpile of drugs"/>
  <result pre="The stockpile of drugs must be adequate, the safety of" exact="treatment" post="must be very high, and costs should ideally be"/>
  <result pre="The antimalarial drug, hydroxychloroquine, is licensed for the chemoprophylaxis and" exact="treatment" post="of malaria and as a disease-modifying antirheumatic drug. It"/>
  <result pre="modelling based on observed drug concentrations and in vitro drug" exact="testing" post="suggest that prophylaxis with hydroxychloroquine at approved doses could"/>
  <result pre="that prophylaxis with hydroxychloroquine at approved doses could prevent SARS-CoV-2" exact="infection" post="and ameliorate viral shedding.5 Clinical trials of hydroxychloroquine treatment"/>
  <result pre="SARS-CoV-2 infection and ameliorate viral shedding.5 Clinical trials of hydroxychloroquine" exact="treatment" post="for COVID-19 pneumonia are underway in China (NCT04261517 and"/>
  <result pre="randomised controlled trial (NCT04304053) to evaluate the efficacy of antiviral" exact="treatment" post="in anyone found to be infected, and the efficacy"/>
  <result pre="Spain, with initial results expected in May, 2020. Identifying a" exact="treatment" post="for the prevention of COVID-19 would change the course"/>
  <result pre="outbreak entirely. References References 1HellewellJAbbottSGimmaAFeasibility of controlling COVID-19 outbreaks by" exact="isolation" post="of cases and contactsLancet Glob Health2020published February 28.10.1016/S2214-109X(20)30074-7 2QifangBiYongshengWuShujiangMeiEpidemiology"/>
  <result pre="and projection of optimized dosing design of hydroxychloroquine for the" exact="treatment" post="of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin Infect"/>
 </snippets>
</snippetsTree>
